Verismo Therapeutics
Philadelphia, PA
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.
verismotherapeutics.comCompany Details
Founded
- 2020
Employees
- Between 10 - 50 employees
Raised
- $44,200,000
Headquarters Location
- Philadelphia, PA
Public
- No
Acquired
- Yes
CEO
Bryan Kim
Founders
- Bryan KimDonald SiegelMichael C. Milone
Company Collections
These are collections Verismo Therapeutics is a part of. Click on the collection name to view similar companies.